Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data

BACKGROUND: Patients with autoimmune disease and on immunotherapy were largely excluded from seminal anti-SARS-CoV-2 vaccine trials. This has led to significant vaccine hesitancy in patients with neuroinflammatory diseases (NID); including, but not limited to: multiple sclerosis (MS), neuromyelitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Epstein, Samantha, Xia, Zongqi, Lee, Annie J., Dahl, Megan, Edwards, Keith, Levit, Elle, Longbrake, Erin E., Perrone, Christopher, Kavak, Katelyn, Weinstock-Guttman, Bianca, Diallo, Fatoumata, Ricci, Adelle, Riley, Claire S., De Jager, Philip L., Farber, Rebecca, Wesley, Sarah F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638239/
https://www.ncbi.nlm.nih.gov/pubmed/34923427
http://dx.doi.org/10.1016/j.msard.2021.103433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638239/
https://www.ncbi.nlm.nih.gov/pubmed/34923427
http://dx.doi.org/10.1016/j.msard.2021.103433

Ejemplares similares